Informing infection

How Inflammatix is aiming for faster, better treatment for infection, sepsis

Inflammatix Inc. measures gene expression patterns in host cells to diagnose and inform treatment decisions for acute infections and sepsis faster than marketed tests. By following the host response, not the pathogen, the company can distinguish bacterial from viral infections and determine the risk of sepsis.

CEO Tim Sweeney told BioCentury Inflammatix is targeting the rapid PCR-based diagnostic for point-of-care use, based on its ability to

Read the full 664 word article

User Sign In